Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNFmonoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, …

prednisone
corticosteroids
small molecule
tumor necrosis factor
methotrexate
  • 111 views
  • 02 Aug, 2021
  • 33 locations
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies

In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated with greater asthma control

  • 22 views
  • 18 Sep, 2021
  • 1 location
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

. Giving monoclonal antibody therapy with chemotherapy may kill more cancer cells. Giving blinatumomab and combination chemotherapy may work better than combination chemotherapy alone in treating patients

combination chemotherapy
lymphoblastic lymphoma
calcium
monoclonal antibodies
blinatumomab
  • 84 views
  • 20 Sep, 2021
  • 119 locations
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection

This is a phase II, double-blind, randomised, controlled, multicentre trial of topical HDIT101 versus placebo. HSV-1-positive patients with at least 6 orolabial herpes lesions in the last 12 months can be included. The patients need to present with 3 herpes lesions within a 9 months observation phase. With the occurrence …

herpes infection
immunoglobulin
  • 42 views
  • 27 Jan, 2021
  • 5 locations
Evaluation of the Response to Monoclonal Antibody Therapy in Severe Asthma: Research of Predictive Biomarkers in Exhaled Air

This study evaluates the change in the composition of Volatil Organic Compounds (VOC) in patients treated by monoclonal antibody for severe asthma.

  • 3 views
  • 21 Feb, 2021
  • 2 locations
Concurrent WOKVAC Vaccination Chemotherapy and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

This phase II trial studies the immunologic response and side effects of using the WOKVAC vaccine in combination with chemotherapy and HER2-targeted monoclonal antibody therapy before surgery in

  • 0 views
  • 09 Sep, 2021
  • 1 location
Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions

The use of monoclonal antibodies (MA) either alone or as part of chemoimmunotherapy in oncology, benign and malignant hematology is expanding. Of the 17 therapeutic MAs approved in 2017 by FDA, 50% of them are indicated for hematologic and oncologic condition. With increasing number of approved agents, therapeutic MAs have …

  • 1 views
  • 25 Jan, 2021
  • 1 location
Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer

effect and safety of watch and wait in patients with dMMR/MSI-H distal RC accessed pCR after PD-1 monoclonal antibody therapy.

obstruction
chemoradiotherapy
transrectal ultrasound
metastasis
monoclonal antibodies
  • 0 views
  • 23 May, 2021
  • 1 location
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced Recurrent or Refractory Hepatic Metastatic Cancer

. Giving combination chemotherapy and monoclonal antibody therapy while using the NovoTTF-100L(P) system may kill more tumor cells.

tumor cells
oxaliplatin
bevacizumab
monoclonal antibodies
neutrophil count
  • 0 views
  • 25 Jan, 2021
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

rituximab, may interfere with the ability of cancer cells to grow and spread. Giving more than one drug (combination chemotherapy) together with monoclonal antibody therapy may kill more cancer cells.

monoclonal protein
prednisone
arrhythmia
rituximab
lymphoma
  • 5 views
  • 24 Jan, 2021
  • 2 locations